# Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

> **NCT07631884** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haihua Yuan** · enrollment: 15 (estimated)

## Conditions studied

- Solid Tumors
- Neoplasms (Cancer / Tumors)
- Advanced Malignant Solid Neoplasm
- Locally Advanced Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- HER2 Expression
- Biliary Tract Neoplasms
- Endometrial Neoplasms
- Urothelial Carcinoma (UC)
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Gastric Neoplasms
- Non-Small Cell Lung Carcinoma (NSCLC)
- Head and Neck Neoplasms
- Cervical Neoplasms

## Interventions

- **DRUG:** Trastuzumab Rezetecan

## Key facts

- **NCT ID:** NCT07631884
- **Lead sponsor:** Haihua Yuan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631884, "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*